2 unchanged sentences
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business.
−Removed: Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
−Removed: On March 1, 2022, I-Mab Biopharma, or I-Mab, filed a lawsuit against the Former Parent and Brendan Eckelman, the Company’s co-founder and Chief Scientific Officer, in the United States District Court for the District of Delaware, C.A.
−Removed: 22-00276-CJB, asserting claims for misappropriation of trade secrets related to Dr.
−Removed: Eckelman’s service as an expert witness for Tracon Pharmaceuticals, Inc., or Tracon, in Tracon’s arbitration against I-Mab.
−Removed: Briefing on motions for summary judgment was recently completed.
−Removed: As of the date of this Quarterly Report, a hearing date on the pending motions has not been set.
−Removed: Trial is currently scheduled to commence in late October 2024.
−Removed: I-Mab is seeking royalty damages and alternative damages in the form of unjust enrichment.
+Added: Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.
+Added: On November 4, 2024, the Company announced a legal victory in the trade secrets case brought by I-Mab Biopharma in the United States District Court for the District of Delaware.
+Added: The jury found in favor of the Company, rejecting all allegations of misappropriation before it.
+Added: I-Mab Biopharma had initiated the lawsuit on March 1, 2022, alleging that the Company and its Chief Scientific Officer, Brendan Eckelman, Ph.D., improperly accessed and used proprietary information related to several of I-Mab Biopharma’s research projects during a prior arbitration proceeding involving I-Mab Biopharma, for which Dr.
+Added: Eckelman served as an expert witness.
+Added: However, the jury found no basis for these claims in finding in favor of the Company.
+Added: Certain matters remain before the Court.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.